Northern Trust’s Inhibikase Therapeutics IKT Stock Holding History
Bought
Maintained
Sold
Other funds holding IKT
SL
Northern Trust's IKT Position: Q3 2026 in Review
Northern Trust increased its Inhibikase Therapeutics (IKT) stake by 14% in Q3 2026, buying an estimated $283K and bringing the position to 1,003,089 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #3050.
Northern Trust first reported a position in IKT in Q3 2021 and has held it in 15 quarters since. 110 funds tracked by Wall St. Rank hold IKT as of Q3 2026.
- Northern Trust held 1,003,089 shares of Inhibikase Therapeutics worth $2.06M as of Q3 2026.
- Northern Trust bought 124,504 Inhibikase Therapeutics shares in Q3 2026, an estimated $283K.
- Inhibikase Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q3 2026, its #3050 holding.
- Northern Trust first reported a position in Inhibikase Therapeutics in Q3 2021 and has held it in 15 quarters since.
- 110 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2026.
Based on Northern Trust's 13F filing for Q3 2026, filed 16 Nov 2026.